Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc. reported a net loss of $8.0 million for the fiscal year ended December 31, 2025, an improvement from a net loss of $14.1 million in the prior year. The company incurred total operating expenses of $8.1 million, consisting of $1.8 million in research and development and $6.3 million in general and administrative expenses, resulting in an operating loss of $8.1 million. The company generated $125,000 in interest income. Cash and cash equivalents were $7.6 million as of December 31, 2025, with total assets of $7.7 million and total shareholders' equity of $5.3 million. The company used $6.8 million in net cash from operating activities but raised $10.6 million from financing activities, primarily through equity offerings and warrant exercises, resulting in a net increase in cash of $3.8 million. The company remains a clinical-stage biopharmaceutical company with no product revenue, focusing on developing its lead antibiotic candidate, ibezapolstat, for Clostridioides difficile infection.

Key Takeaways